Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma

Area of Science:

• Oncology
• Bioinformatics
• Genomics

Background:

• Clear cell renal cell carcinoma (ccRCC) is a complex cancer with poorly understood molecular drivers.
• Tumor heterogeneity in ccRCC necessitates advanced analytical approaches to identify key molecular targets.

Purpose of the Study:

• To identify critical genes and molecular pathways involved in ccRCC pathogenesis using integrated bioinformatics.
• To discover potential therapeutic targets and prognostic biomarkers for ccRCC.

Main Methods:

• Differential gene expression analysis across three public datasets.
• Weighted gene co-expression network analysis (WGCNA) to identify relevant gene modules.
• Gene Ontology (GO) and KEGG pathway enrichment analyses.
• Hub gene identification and validation using the GEPIA database.
• Multivariate Cox regression for prognostic factor analysis.

Main Results:

• Identified 1387 differentially expressed genes (673 upregulated, 714 downregulated).
• The blue module from WGCNA, enriched in cell cycle and metabolic pathways, strongly correlated with ccRCC stage and grade.
• Discovered 9 key genes (PTTG1, RRM2, TOP2A, UHRF1, CEP55, BIRC5, UBE2C, FOXM1, CDC20) associated with ccRCC progression and prognosis.
• A risk score based on these 9 genes proved to be an independent prognostic factor.
• Identified potential small molecule drugs for ccRCC treatment, with some showing biomarker potential.

Conclusions:

• This study successfully identified 9 prognostic genes crucial for ccRCC.
• Candidate small molecule drugs were pinpointed, offering new therapeutic avenues for ccRCC.
• The identified gene signature serves as a valuable prognostic tool for ccRCC patients.